PIT Study Design: Phase IB/II First Line Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS Wild-Type Patients with Metastatic Colorectal Cancer

被引：0
|
作者：
Price, T. [1 ,2 ,3 ,4 ]
Rico, G. Tapia [1 ]
Williams, J. [1 ]
Yeend, S. [1 ]
Lo, L. [1 ]
Patel, D. [1 ,2 ]
Tebbutt, N. [4 ,5 ]
Shapiro, J. [4 ,6 ]
Burge, M. [4 ,7 ]
Gebski, V. [3 ]
Townsend, A. [1 ,2 ,4 ]
机构：
[1] Queen Elizabeth Hosp, Adelaide, SA, Australia
[2] Univ Adelaide, Adelaide, SA, Australia
[3] NHMRC Clin Trials Ctr, Sydney Med Sch, Sydney, NSW, Australia
[4] AGITG, Sydney, NSW, Australia
[5] Austin Hlth, Melbourne, Vic, Australia
[6] Monash Univ, Melbourne, Vic, Australia
[7] Royal Brisbane Hosp, Brisbane, Qld, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
ORAL CHEMOTHERAPEUTIC-AGENT; XENOGRAFTS; EFFICACY; TAS-102;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [31] A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT).
    Townsend, Amanda Rose
    Pirc, Louise
    Cooper, Pamela
    Tebbutt, Niall C.
    Karapetis, Christos Stelios
    Singhal, Nimit
    Price, Timothy Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
    Elez, Elena
    Pericay, Caries
    Valladares-Ayerbes, Manuel
    Bando, Inmaculada
    Safont, Maria Jose
    Gallego, Javier
    Gravalos, Cristina
    Arrivi, Antonio
    Carrato, Alfredo
    Conde, Veronica
    Jose Ortiz, Maria
    Lopez, Carlos
    Alonso, Beatriz
    Ruiz de Mena, Inmaculada
    Diaz-Rubio, Eduardo
    Tabernero, Josep
    Aranda, Enrique
    BRITISH JOURNAL OF CANCER, 2019, 121 (05) : 378 - 383
  • [33] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
    Garrido-Laguna, I.
    McGregor, K. A.
    Wade, M.
    Weis, J.
    Gilcrease, W.
    Burr, L.
    Soldi, R.
    Jakubowski, L.
    Davidson, C.
    Morrell, G.
    Olpin, J. D.
    Boucher, K.
    Jones, D.
    Sharma, S.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1257 - 1264
  • [34] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
    I. Garrido-Laguna
    K. A. McGregor
    M. Wade
    J. Weis
    W. Gilcrease
    L. Burr
    R. Soldi
    L. Jakubowski
    C. Davidson
    G. Morrell
    J. D. Olpin
    K. Boucher
    D. Jones
    S. Sharma
    Investigational New Drugs, 2013, 31 : 1257 - 1264
  • [35] Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase 2 VELO trial
    Ciardiello, D.
    Napolitano, S.
    De Falco, V.
    Martini, G.
    Martinelli, E.
    Della Corte, C.
    Esposito, L.
    Famiglietti, V.
    Di Liello, A.
    Avallone, A.
    Cardone, C.
    De Stefano, A.
    Montesarchio, V.
    Zampino, M.
    Fazio, N.
    Del Tufo, S.
    Di Maio, M.
    De Vita, F.
    Altucci, L.
    Marrone, F.
    Ciardiello, F.
    Troiani, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S171 - S172
  • [36] Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Fakih, Marwan G.
    Knox, Hediyyih N.
    Maglinte, Gregory A.
    Hjelmgren, Jonas
    Barber, Beth
    Schwartzberg, Lee S.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 619 - 628
  • [37] A phase II trial of panitumumab with irinotecan and S-1 (IRIS) as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer.
    Shimoyama, Rai
    Kimura, Tetsuo
    Takaoka, Toshi
    Sakamoto, Kazuki
    Kawamoto, Shunji
    Yoshizaki, Koji
    Negoro, Yuji
    Goda, Fuminori
    Tsuji, Akihito
    Nakayama, Tsuyoshi
    Miyamoto, Hiroshi
    Takayama, Tetsuji
    Niitsu, Yoshiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [38] A single-arm, multicenter, phase II study of panitumumab in combination with capecitabine/oxaliplatin in first line, wild-type KRAS metastatic colorectal cancer patients.
    Pectasides, Dimitrios G.
    Karavasilis, Vasilios
    Kotoula, Vassiliki
    Samantas, Epaminontas
    Alexopoulou, Zoi
    Zagouri, Flora
    Syrigos, Konstantinos N.
    Koureas, Andreas
    Dionysopoulos, Dimitrios
    Lazaridis, Georgios
    Efstratiou, Ioannis
    Apessou, Dimitra
    Pentheroudakis, George E.
    Papaxoinis, George
    Fountzilas, George
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial.
    Shitara, Kohei
    Muro, Kei
    Watanabe, Jun
    Yamazaki, Kentaro
    Ohori, Hisatsugu
    Shiozawa, Manabu
    Yasui, Hirofumi
    Oki, Eiji
    Sato, Takeo
    Naito, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Soeda, Junpei
    Yamamoto, Kouji
    Yamashita, Riu
    Akagi, Kiwamu
    Ochiai, Atsushi
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 11 - 11
  • [40] Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer
    Hocking, Christopher M.
    Price, Timothy J.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2014, 7 (01) : 20 - 37
12345